Abstract: This invention relates to novel compounds which up-regulate LDL receptor (LDL-r) expression and to processes for their preparation, pharmaceutical compositions containing them and their medical use. More particularly, this invention relates to novel aromatic piperidines and their use in therapy.

Abstract: This invention relates to novel compounds which up-regulate LDL receptor (LDL-r) expression and to processes for their preparation, pharmaceutical compositions containing them and their medical use. More particularly, this invention relates to novel aromatic piperidines and their use in therapy.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof, wherein:

Abstract: A compound of formula (1) and pharmaceutically acceptable salts, solvates and hydrolysable esters thereof: wherein R1 and R2 are independently H or C1-3 alkyl or R1 and R2 which are bonded to the same carbon atom may together with the carbon atom to which they are bonded form a 3-5 membered cycloalkyl ring; X1 represents O or S; Each R3, R4, R8 and R9 independently represents H, halogen, —CH3 and OCH3; R5 represents H or C1-6 alkyl or R4 and R5 together form a 3-6 member cycloalkyl ring. X2 represents NH, NCH3 or O; One of Y and Z is N, and the other is O or S; R6 represents phenyl or pyridyl (wherein the N is in position 2 or 3) and is optionally substituted by one more halogen, CF3, C1-6 straight or branched alkyl (optionally substituted by halogen), with the provision that when R6 is pyridyl, the N is unsubstituted.

Abstract: These are provided compounds of formula I ##STR1## wherein A represents an oxygen or a sulphur atom, a bond or a group (CH.sub.2).sub.1 NR.sup.9 (where 1 represents zero or 1 and R.sup.9 represents a hydrogen atom or a methyl group); B represents a C.sub.1-4 alkylene chain optionally substituted by a hydroxyl group, except that the hydroxyl group and moiety A can not be attached to the same carbon atom when A represents an oxygen or sulphur atom or a group (CH.sub.2).sub.1 NR.sup.9, or when A represents a bond B may also represent a C.sub.2-4 alkenylene chain; R.sup.3 represents a hydrogen atom or a C.sub.1-4 alkyl group; m represents 1 or 2; R.sup.7 represents a hydrogen atom or R.sup.3 and R.sup.7 together form a group --(CH.sub.2).sub.n -- where n represents 1 or 2. These compounds can sensitize multidrug-resistant cancer cells to chemotherapeutic agents and may be formulated for use in therapy, particularly to improve or increase the efficacy of an antitumor drug.

Abstract: This invention relates to novel piperidines substituted on the nitrogen atom with a (phenyloxo alkyl) group as well as the processes for their production.

Abstract: This invention relates to novel tri-substituted guanidines linked to a piperidine ring.More specifically, it relates to cyanoguanidines of formula I ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 are substituentsn is an integer of zero to 1n' is an integer of zero to 1A and B are --CH.sub.2 --, CHOH, --CO-- or a single bondas well as the acid addition salts thereof with a mineral or organic acid.The compounds have interesting pharmacological properties which make them useful as active ingredient of medicines, e.g. antihypertensives.

Abstract: This invention relates to new chemical compounds which are derivatives of 2,5-diaminodiazoles.It relates more particularly to new 2-amino 5-(aralkylamino piperidino alkyl) diazoles.These compounds and the acid addition salts thereof have interesting therapeutical properties, particularly anti-hypertensive properties which make them useful as active ingredient of pharmaceutical compositions.

Abstract: This invention relates to benzodioxanylalkylpiperidines, to processes for producing them and to the pharmaceutical compositions containing such compounds as active ingredient.This invention also relates to a method for treating hypertension in hypertensive mammals.